Biotech and Pharma Industry News | BioPharma Dive
BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
The top biopharma conferences in 2025 | BioPharma Dive
Oct 1, 2024 · American Association of Cancer Research Annual Meeting. April 25 - 30, 2025 Chicago. While the American Society of Clinical Oncology’s meeting often gets billed as the field’s largest conference, AACR has become an equally major gathering for cancer research, particularly earlier-stage findings on new drug mechanisms of action or treatment modalities.
Drugmakers are racing to find the next Wegovy. These obesity …
Oct 10, 2024 · Within the pharmaceutical industry, a multibillion-dollar race is underway to top Novo Nordisk’s and Eli Lilly’s in-demand obesity drugs. Dozens of companies, large and small, have set out to test experimental medicines they claim could be more potent, convenient or have fewer side effects than Novo’s Wegovy and Lilly’s Zepbound.
BridgeBio heart drug approved by FDA, setting up battle with Pfizer
Nov 22, 2024 · Notably, the drug is approved to prevent hospitalization or death resulting from heart complications of transthyretin amyloidosis with cardiomyopathy. Investors had been skeptical BridgeBio would earn such a distinction from regulators, leading to doubts about Attruby’s commercial prospects.. BridgeBio priced Attruby at just under $19,000 for a 28-day supply, translating to an annual list ...
Sanofi may have found a buyer for its consumer health business
Oct 11, 2024 · Opella sells well-known products like Allegra and Icy Hot, and, according to Sanofi, employs more than 11,000 people. The unit also operates in 100 countries, manages 13 manufacturing sites and operates four research centers.
AbbVie to acquire a J&J-backed brain drugmaker for $1.4B
Oct 28, 2024 · AbbVie has agreed to acquire a young company with drugmaking technology from Johnson & Johnson and an experimental treatment for Alzheimer’s disease that’s in the first stage of human testing.. The deal, announced Monday, is expected to close by the end of the year, and has AbbVie buying all the outstanding shares of Aliada Therapeutics for $1.4 billion in cash.
The golden era of GLP-1 drugs: Where we are and what comes next
Sep 23, 2024 · A guidance from the U.S. FDA (draft updated in March 2020) requires data on cardiovascular events in new T2D drug development programs.As a result, dedicated cardiovascular safety trials were implemented. Many demonstrated beneficial effects of GLP-1 RAs on the heart and kidneys in patients with T2D (with and without preexisting conditions), with those effects thought to be largely independent ...
Drug patents protect pharma profits. Track when they’ll expire.
May 8, 2024 · Patents reward drugmakers for their inventions and, effectively, the large sums of money they invest in research and development. The legal monopoly that patents provide keeps generic copies at bay for many years, even decades, and allows pharmaceutical companies to set higher prices than they otherwise could.
Novartis wagers more than $1B on gene therapies for the nervous …
Nov 21, 2024 · The Kate acquisition comes almost a year and a half after Novartis agreed to buy DTx Pharma, a startup aiming to use RNA drugmaking technology to treat neurological diseases. The deal, which carried a $500 million upfront payment, handed Novartis a few experimental drugs that had yet to reach human testing.
After Pfizer deal, former Seagen CEO returns to lead oncology …
Oct 28, 2024 · After Pfizer deal, former Seagen CEO returns to lead oncology startup David Epstein has joined Ottimo Pharma, which is developing a dual-targeting antibody drug that board member James Sabry claims could “change the face of cancer immunotherapy.”